Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07113067 · ClinicalTrials.gov registry record · Phase 1
Accelerated rTMS vs. Sham for Stroke Apathy
A Phase 1 study of Stroke and Motivation, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT07113067 is a Phase 1 study of Stroke and Motivation that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 40 participants, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07113067, a Phase 1 study of Stroke and Motivation, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact the people who take care of them. There are currently no FDA-approved treatments to help with apathy, and other services like therapy may be difficult to access for people who have had a stroke. To address this problem, investigators are conducting a study to find out if a form of treatment called repetitive transcranial magnetic stimulation (rTMS) can be safe and helpful for people struggling with apathy after a stroke. This study will apply a new form of rTMS which can be delivered quickly to a part of the brain called the medial prefrontal cortex (mPFC). This study will help establish whether this treatment is safe, comfortable, and effective for people with apathy after a stroke, and will help researchers develop new forms of treatment.
Conditions Studied
Interventions
- DEVICE MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active)
- DEVICE MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham)
- OTHER Brainsight Neuronavigation System
Study Locations (1)
South Carolina
- Medical University of South Carolina Brain Stimulation Lab - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-08-08 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07113067
The ClinicalTrials.gov registry entry for NCT07113067 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,016-participant average among 454 other Stroke trials with a reported enrollment target (100% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Stroke appearing as the primary indexed condition, and to 3 interventions - of which MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active) is the first listed.
NCT07113067 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT07113067 about?
NCT07113067 is a clinical study titled "Accelerated rTMS vs. Sham for Stroke Apathy". Apathy is a common set of symptoms seen in many people following a stroke. Apathy occurs when a person has lost motivation, becomes withdrawn, and stops doing things that used to be important to them. Apathy has a large negative impact on a person's quality of life, and can also have a large impact ...
What is the current status of trial NCT07113067?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2025-08-08. Estimated completion is 2027-06-30.
What conditions does trial NCT07113067 study?
This clinical trial studies the following conditions: Stroke, Motivation, Stroke Sequelae, Apathy, Stroke/Brain Attack.
What interventions are being tested in trial NCT07113067?
The interventions under investigation include: MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active) (DEVICE), MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham) (DEVICE), Brainsight Neuronavigation System (OTHER).
Who is sponsoring clinical trial NCT07113067?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07113067 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Infliximab Therapy for Dolichoectactic Vertebrobasilar Aneurysms
RECRUITING · Phase 1
-
Hybrid Robot+FES Stroke Rehabilitation
RECRUITING · Phase 1
-
Vibrotactile Stimulation for Upper-Extremity Stroke Rehabilitation
RECRUITING · Phase 1
-
Facilitating Neuroplastic Changes of Acute Stroke Survivors
RECRUITING · Phase 1
-
Identifying Personalized Brain States Predicting Residual Corticospinal Tract Output After Stroke
RECRUITING · Phase 1
-
Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.